Transforming Lives

Through a new class of safe, durable cancer treatments.

In The News

    • MAR 29 2018

    OncologyTube: Dr. Chi talks about his ONC201 trial in H3 K27M-mutant gliomas

    In the videos below, Dr. Andrew Chi talks about ONC201 and his Phase II – Adults with Recurrent H3 K27M High-grade Glioma (NCT03295396) at NYU Langone. H3 K27M-mutant gliomas are known to overexpress DRD2, the target that ONC201 utilizes to drive its anti-cancer effects. Andrew S. Chi, MD PhD, Chief of Neuro-Oncology and the Codirector of

    • MAR 21 2018

    Fox Chase Cancer Center Researchers Uncover ONC201 Immune-oncology Effects

    “Immune cell activation in the tumor and inhibition of metastasis with an oral, infrequently administered and well tolerated small molecule provides an attractive treatment option for patients. Immune activation is recognized as an important requirement to achieve durable and complete remissions in conjunction with standard-of-care therapies,” said El-Deiry. “We discovered ONC201 through its ability to